Supplementary Information

Chemoproteomic profiling reveals cellular targets of nitro-fatty acids

Ming-Yu Fang^{a,g}, Kuan-Hsun Huang^{b,g}, Wei-Ju Tu^c, Yi-Ting Chen^{c,d,e}, Pei-Yun Pan^b, Wan-

Chi Hsiao^{a,f}, Yi-Yu Ke^b, Lun K. Tsou^b, Mingzi M. Zhang^{a*}

^aInstitute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan,

Miaoli, 35053, Taiwan

^bInstitute of Biotechnology and Pharmaceutical Research, National Health Research

Institutes, Zhunan, Miaoli, 35053, Taiwan

^cGraduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University,

Taoyuan, Taiwan

^dDepartment of Biomedical Sciences, College of Medicine, Chang Gung University,

Taoyuan, Taiwan

^eDepartment of Nephrology, Chang Gung Memorial Hospital, Linkou Medical Center,

Taoyuan, Taiwan

^fInstitute of Biotechnology, National Tsing Hua University, Hsinchu, 30013, Taiwan

^gEqual contribution

*To whom correspondence may be addressed:

zhangmz@nhri.edu.tw, 35 Keyan Road, Zhunan, Miaoli, 35053, Taiwan

Supplementary Figures	Page S2-S10
Supplementary Tables Legends	Page S11
Supplementary Materials and Methods	Page S12-S18
Supplementary References	Page S19-S20

Supplementary Figures



Supplementary Figure 1. Protein nitro-alkylation is a reversible protein modification. (A) Chemical structures of selected positional isomers of nitro-oleic acids, 9-nitro-oleate and 10nitro-oleate. Also shown are the chemical structures of nitro-oleate probes for the detection of nitro-alkylated proteins, including the widely used biotinylated nitro-oleate [1], and the alkynyl-9-nitro-oleate probe 8 from this study. (B) Nitro-fatty acids form reversible protein adducts with the thiols of cysteine residues of target proteins via Michael addition.

5° 3°	
	- 10 - 1 - 1 - 15 - 1 - 1 - 10 - 1 - 1 - 12 - 1 - 1 - 150 - 1 - 1 - 150 - 1 - 1 - 150 - 1 - 1 - 150 - 1 - 1 - 150 A G A C C R F L P L Q S Q C P E G A G D A V M Y A S T E C H A E V T P S Q H G N R T F S Y T L E D H T K2201 → C38 C38
3M	
7M	
5'	
3'	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
3M	
7M	
	and wanter and the second of the second of the second of the second of the second
5'	240 250 260 270 280 299 310 310 320 330 340 350 360 370 380
3'	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $
3M	C151
7M	
	mine man water and the second of the second
5'	ATGTACCAGATCGACAGCGTTGTCCGTGCAGTGACTTCCTGGTGCAGCAGCTGGACCCCAGCAATGCCATCGGCAACGCCAACTTCGCTGAGCAGATTGGCTGTGGAGTTGCACCAGCGTGCCCGGGAGTACATCTACATGCAT
3'	TACATGGTCTAGCTGTCGGCAACGGGCGGCGTCGTCGAACGGACCGCGCGCG
3М	
7M	MANNA AND AND AND AND AND AND AND AND AND
	annahalaamaanaamaanaanaanaanaanaanaanaanaanaana
5'	360 370 380 390 400 410 420 430 440 450 460 470 480 490 500
3'	$\frac{1}{1}$
3M	
7 M	TTTGGGGGAGGTGGCCAABGAGGTGTTTCAACCTGTCCCAC



Supplementary Figure 2. Sanger sequencing traces confirming the presence of indicated mutations in 3M and 7M KEAP1 mutants. 3M: C151S, C273W, C288E. 7M: C38S, C151S, C226S, C257S, C273W, C288E, C489S.

5	5. tggagatcatatagacaatcaagtgcaaacctgctgtgttttgctcctgatctgattattaatgagcagagaatgacta 	ctaccctgcatgtacg gatgggacgtacatgc	accaatgtaaacacatgctgtatgtttcc
	610 615 620 625 630 635 W R S Y R Q S S A N L L C F A P D L I I N E Q R M T GR?FL →	L P C M Y I	, , , , 645 , , , , , 650 DQCКНМLYVS
	C622	C638	C643
wt	ντ Τσσασατοατατασασαατοαασοσοασοσοσοσοσοσοσο	CTACCCTGCATGTACG	ACCAATGTAAACACATGCTGTATGTTTCC
	Man Markan Ma	470	MMMMMMMM 450 440 440 431
C622S	S TEGAGATCATATAGACAATCAAGTGCAAACCTGCTG <mark>A</mark> GTTTTGCTCCTGATCTGATTATTAATGAGCAGAAGAATGACT	CTACCCTGCATGTACG	ACCAATGTAAACACATGCTGTATGTTTCC
C6388	MMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMM		
00005			Λ
C6438	MMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMM		450 450 440 431
	and the second	470 460	430 430 430
C665S	S TEGAGATCATATAGACAATCAAGTGCAAACCTGCTGTGTTTTGCTCCTGATCTGATTATTAATGAGCAGAAGAATGACT	CTACCCTGCATGTACG	ACCAATGTAAACACATGCTGTATGTTTCC
C736S	MMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMM		
	man marken and a marken an	MAMM	Manna
5055	550 540 530 520 510 490 480 TGGAGATCATATAGACCAACCAAGTGCAAACCTGCTGAGTTTTGCTCCCTGATCATATAATGAGCAGAAGAATGACCTGCTGAGTATTATAATGAGCAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGACGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAATGACCAGAGAGAG	470 460 CTACCCAGCATGTACGA	450 440 430 ACCAA <mark>A</mark> GTAAACACATGCTGTATGTTTCC
5075	Man	170 470	MMMMMMMM 450 440 430
4C>S	TGGAGATCATATAGACAATCAAGTGCAAACCTGCTG <mark>A</mark> GTTTTGCTCCTGATCTGATTATTAATGAGCAGAGAATGACT	CTACCC <mark>A</mark> GCATGTACGA	ACCAATGTAAACACATGCTGTATGTTTCC
(040)		470	450 440 430
4C>S (C638)	TGGAGATCATATAGACAATCAAGTGCAAACCTGCTGGTGTTTTGCTCCCGATCTGATTATTAATGAGCAGAAGAATGACC		
4C>S (C665)			

5'	tctgagttacacaggcttcaggtatcttatgaagagtatctctgtatgaaaaccttactgcttctcttctagttcctaaggacggtctgaagagccaagagctatttgatgaaattagaat
3,	agactcaatgtgtccgaagtccatagaatacttctcatagagacatactttggaatgacaagagagag
	GKAL
wt	TCTGAGTTACACAGGCTTCAGGTATCTTATGAAGAGTATCTCTGTATGAAAACCTTACTGCTTCTCTTCTGATTCAAGGACGGTCTGAAGAGCCAAGAGCCAATTGATGAAATTAGAATG
	and marked when the second and the second se
C622S	TCTGAGTTACACAGGCCTTCAGGTATCTTATGAAGAGTATCTCTGTATGAAAACCTTACTGCTTCTCTCTC
	and marked marked and and and and and and and and and an
C638S	τοτολογιστικό το
	www.www.man.man.man.man.man.man.man.man.man.man
C643S	TCTGAGTTACACAGGCTTCAGGTATCTTATGAAGAGTATCTCTGTATGAAAACCTTACTGCTTCTCTTCTGTTCAGTTCCTAAGGACGGTCTGAAGAGCCAAGAGCTATTTGATGAAATTAGAATG
	www.www.www.www.www.www.www.www.www.ww
C665S	TCTGAGTTACACAGGCTTCAGGTATCTTATGAAGAGTATCTCAGTATGAAAACCTTACTGCTTCTCTTCTGATTCAAGGACGGTCTGAAGAGCCAAGAGCCAATTGAATAGAATTAGAATG
	www.hammer.a
C736S	TCTGAGTTACACAGGCTTCAGGTATCTTATGAAGAGTATCTCTGTATGAAAACCTTACTGCTTCTCTCTC
	www.how.www.www.www.www.www.www.www.www.
5C>S	TCTGAGTTACACAGGCTTCAGGTATCTTATGAAGAGTATCTCAGTACTGCAAAACCTTACTGCTTCTCTCTC
4C>S (C643)	TCTGAGTTACACAGGCTTCAGGTATCTTATGAAGAGTATCTCAGTATGAAAACCTTACTGCTTCTCTTCTGATTCAGGTCCTAAGGACGGTCTGAAGAGCCAAGAGCCAATTGATGAAATTAGAATG
()	www.www.www.www.www.www.www.www.www.ww
4C>S (C638)	TCTGAGTTACACAGGCTTCAGGTATCTTATGAAGAGTATCTCAGTATGAAAACCTTACTGCTTCTCTTCAGTTCCTAAGGACGGTCTGAAGAGCCAAGAGCCAATTTGATGAAATTAGAATG
	www.how.www.www.www.www.how.www.how.how.
4C>S (C665)	TCTGAGTTACACAGGCTTCAGGTATCTTATGAAGAGTATCTCTGTATGAAAACCTTACTGCTTCTCTTCTGTTCAGTTCCTAAGGACGGTCTGAAGAGCCAAGAGCCTATTTGATGAAATTAGAATG
	www.how.www.www.www.www.www.www.www.www.

5	acctacatcanagagctaggaaaagccattgtcaagagggaaaggaaa
3	
	, , , , , , , , , , , , , , , , , , ,
wt	ACCTACATCAAAGAGCTAGGAAAAGCCATTGTCAAGAGGGAAGGAA
C622S	ACCTACATCAAAGAGCTAGGAAAAGCCATTGTCAAGAGGGAAAGGAAACTCCAGCCAG
	$M_{1}^{1} M_{1}^{1} M_{1} M_{1}^{1} M_{1} M_{1}^{1} M_{1} M_{1} M_{1} M_{1} M_{1} M_$
C638S	ACCTACATCAAAGAGCTAGGAAAAGCCATTGTCAAGAGGGAAGGGAAACTCCAGCCAG
	$M_{1}^{M} M_{1}^{M} M_{1$
C643S	ACCTACATCAAAGAGCTAGGAAAAGCCATTGTCAAGAGGGAAAGGGAAACTCCAGCCAG
	$M_{\mathcal{M}} (\mathcal{M}_{\mathcal{M}}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M})) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M})) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M})) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M})) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M})) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M})) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M}) (\mathcal{M})) (\mathcal{M}) (\mathcal{M}$
C665S	ACCTACATCAAAGAGCTAGGAAAAAGCCATTGTCAAGAGGGAAAGGGAAACTCCAGCCAG
	$M_{1} M_{1} M_{1$
C736S	ACCTACATCAAAGAGCTAGGAAAAGCCATTGTCAAGAGGGAAAGGGAAACTCCAGCCAG
	M.M.M.M.M.M.M.M.M.M.M.M.M.M.M.M.M.M.M.
5C>S	ACCTACATCAAAGAGCTAGGAAAAAGCCATTGTCAAGAGGGAAAGGGAAACTCCAGCCAG
	Mar
4C>S	ACCTACATCAAAGAGCTAGGAAAAGCCATTGTCAAGAGGGAAAGGGAAAGTCCAGCCAG
(C643)	
4C>S	ACCTACATCAAAGAGCTAGGAAAAGCCATTGTCAAGAGGGAAGGAA
(C638)	
4C>S	200 270 200 270 200 270 200 270 200 190 ACCTACATCAAAGAGCTAGGAAAAGCCATTGTCAAGAGGGAAAGTGCCAGGCAGG
(C665)	
	M. Insome Manhan Main Maria Manhan Mana Mana Mana Mana Mana Mana M

5'	cttaactattgcttccaaacatttttggataagaccatgagtattgaattccccgagatgttagctgaaatcatcaccaatcagataccaaaatattcaaatggaaatatcaaaaaacttctg
3.	gaattgataacgaaggtttgtaaaaacctattcggtactcataacttaaggggctctacaatcgactttagtagtggttagtcatggttttataagtttacctttatagtttttgaagac 735 740 745 750 755 760 755 770
	L N Y C F Q T F L D K T M S I E F P E M L A E I I T N Q I P K Y S N G N I K K L L GR-FL→
	C736
wt	CTTAACTATTGCTTCCAAAACATTTTTGGATAAGACCATGAGTATTGAATTCCCCGAGATGTTAGCTGAAATCATCACCAATCAGATACCAAAATATTCAAAATGGAAATATCAAAAAACTTCTG
	man have been and have been an
C622S	180 170 160 150 140 130 120 110 100 90 80 70 € CTTAACTATTGCTTCCAAACATTTTTGGATAAGACCATGAGTATTGAATTCCCCGAGATGTTAGCTGAAATCATCACAATACCAAAATATTCCAAATGGAAATATCCAAAAAACTTCTG 6 6 70 6 70 6 70 6 70 6 70 6 70 6 70 6 70 6 70 6 70 6 70 70 6 70 70 6 70 70 70 6 70
C638S	CTTAACTATTGCTTCCAAACATTTTTGGATAAGACCATGAGTATTGAATTCCCCGAGATGTTAGCTGAAATCATCACCAATCAGATACCAAAAAATATTCAAAATGGAAATATCAAAAAACTTCTG
0(100	
C6438	
	win with with which with the w
C665S	CTTAACTATTGCTTCCAAACATTTTTGGATAAGACCATGAGTATTGAATTCCCCGAGATGTTAGCTGAAATCATCACCAATCAGATACCAAAATATTCAAAATGGAAATATCAAAAAACTTCTG
	man how
C736S	180 170 160 150 140 130 120 110 100 90 80 70 60 CTTAACTATAACATATTTGAACATGAACATTGAATTGGAATTGCCCGAGATGTTAGCTGAAATCATCACCAATCAGATACCAAAATATTCGAAATGGAAATATCCAAAAAACTTCTG 100 90 80 70 60
5C>S	CTTAACTAT <mark>A</mark> GCTTCCAAACATTTTTGGATAAGACCATGAGTATTGAATTCCCCGAGATGTTAGCTGAAATCATCACCAATCAGATACCAAAATATTCAAAATGGAAATATCAAAAAACTTCTG
4C>S	180 170 160 150 140 130 120 110 100 90 80 70 4 ICTTAACTATĂĞGCTTCCAAACATTTTGGATAAGACCATGAGATTGAATTCCCCGAGATGTTAGCTGAAATCATCACAATACCAAACATTTCAAAAAGGGAAATATCCAAAAAACTTCTG
(C643)	
4C>S	CTTAACTAT <mark>A</mark> GCTTCCAAACATTTTTGGATAAGACCATGAGTATTGAATTCCCCCGAGATGTTAGCTGAAATCATCACCAATCAGATACCAAAATATTCAAAATGGAAATATCAAAAAACTTCTG
(0038)	man have have a second of the
4C>8	180 120 100 100 100 100 100 100 100 100 10
(C665)	

Supplementary Figure 3. Sanger sequencing traces confirming the presence of indicated cysteine to serine mutations in NR3C1-LBD. 5C>S refers to the mutant with all 5 cysteines (C622, C638, C643, C665, C736) in the LBD mutated to serine. 4C>S (Cxxx) refers to mutants with 4 of the 5 cysteines in the LBD mutated to serine, with the indicated cysteine remaining intact.



Supplementary Figure 4. Filter criteria for the identification of nitro-alkylated proteins from THP1 cells. Each proteomics run is an independent biological repeat. For each proteomics run, from the list of proteins obtained in the alk-9-NO₂-OA samples that were treated for 15 min (short) and 3.5 h (long), we excluded proteins that were also identified in either of the two negative control samples (9-NO₂-OA). Filtering for proteins that were either identified in ≥ 2 short or ≥ 2 long samples yielded 274 proteins as represented in Figure 2D. Filtering for proteins that were identified ≥ 3 times in the total of 6 samples yielded and excluding proteins that were similarly enriched using alk-OA yielded 184 proteins. These proteins were used for bioinformatics analyses represented in Figure 3 and listed in Supplementary Table 1.



Supplementary Figure 5. Selective enrichment of selected nitro-alkylated proteins at lower probe concentrations. Lysates from THP1 macrophages treated with the lipids at the indicated concentrations for 15 min were reacted with biotin-azide via CuAAC. Protein samples before NeutrAvidin enrichment (input) and after elution were immunoblotted for the ESYT2 and NR3C1.

Supplementary Tables Legends

Supplementary Table 1. High-confidence list of nitro-alkylated proteins from THP1 macrophages identified by chemoproteomics study. Proteins are ranked by the total number of peptide spectrum matches (PSMs) identified in alk-9-NO₂-OA samples. (.xlxs)

Supplementary Table 2. Comparative analysis of high confidence nitro-alkylated protein list from this study with protein targets of other indicated electrophilic compounds. Proteins found to be modified by the indicated electrophiles in their respective studies are highlighted in green. IA, iodoacetamide [2]. DMF, dimethyl fumarate [3]. HNE, 4-hydroxy-2-nonenal and ONE, 4-oxo-2-nonenal [4,5]. Sulforaphane [6]. BMK, bromomethyl ketone [7]. Curcumin [8,9]. HD, 2-trans-hexadecenal [10]. CDDO-Im, imidazole derivative of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid [11]. 2BP, 2-bromopalmitate [12,13]. (.xlsx)

Supplementary Materials and Methods

Chemical synthesis of clickable alk-9-NO₂-OA probe.

$$Br \xrightarrow{7} OH \xrightarrow{CrO_3, H_2SO_4} Br \xrightarrow{0} OH$$
Acetone, 0°C to rt

9-bromononanoic acid 1: To the solution of 2.5 M Jones' reagent (30 mL, 76.18 mmol, 1.7 eq.) in 10 mL of acetone was added 9-bromononanol (10 g, 44.81 mmol) in acetone (10 mL) at 0 °C. After reaction was completed, the solution mixture was added water (100 mL) and Et₂O (100 mL). After phase separation, the aqueous layer was extracted with Et₂O (50 mL x 3). The combined organic layer was washed with 1.0 N NaOH (30 mL x 3). The aqueous layers were combined and washed with DCM (30 mL x 2) to remove nonpolar impurities. The aqueous layer was acidified to pH 2 with conc. HCl and extracted with Et₂O (30 mL x 3). The combined organic layers were washed with brine (50 mL x 2), dried over MgSO₄, filtered, and concentrated in vacuo to provide 9-bromononanoic acid 1 (6.68 g, 63%). ¹H NMR (CDCl₃, 400 MHz): δ 3.38 (2H, t, *J* = 9.2 Hz), 2.33 (2H, *J* = 10 Hz), 1.88-1.78 (2H, m), 1.64-1.57 (2H, m), 1.42-1.40 (2H, m), 1.38-1.30 (6H, m); ¹³C NMR (CDCl₃, 176 MHz): δ 180.51, 34.20, 34.04, 32.88, 29.14, 29.02, 28.65, 28.19, 24.71 [14].

Jone's reagent preparation: Dissolve CrO_3 (25 g, 0.25 mol) in H₂O (75 mL) then was added conc. H₂SO₄ (25 mL) slowly at 0 °C. The concentration of the solution prepared by this procedure is 2.5 M.

$$Br \xrightarrow{0}_{7} OH \xrightarrow{TFAA, tBuOH}_{DCM, 0^{\circ}C \text{ to } rt} Br \xrightarrow{0}_{7} O$$

Ester 2: To a solution of 9-bromononanoic acid 1 (208 mg, 0.88 mmol) in DCM (4.4 mL) was added dropwise TFAA (405 mg, 1.93 mmol, 2.2 eq.) at 0 °C. The resulting mixture was stirred for 2.5 h before addition *t*BuOH (228 mg, 3.07 mmol, 3.5 eq.) at 0 °C. The resulting mixture was slowly warmed to RT. After reaction was completed, resulting mixture was added 10 mL of NaHCO₃ (sat. aq) and extracted with Et₂O (10 mL x 3). The combined organic layers were washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo to give ester **2** (238 mg, 93%). ¹H NMR (400 MHz, CDCl₃): δ 3.38 (2H, t, *J* = 7.2 Hz), 2.18 (2H, 5, *J* = 7.6 Hz), 1.86-1.79 (2H, m), 1.59-1.52 (overlap with water residual, 2H, m), 1.43-1.38 (11H, m), 1.29 (6H, br); ¹³C NMR (176 MHz, CDCl₃): δ 173.20, 79.91, 35.59, 33.93, 32.85, 29.16, 29.02, 28.65, 28.19, 28.17, 25.09 [15].



tert-butyl 9-nitrononanoate 3: To the flask was added NaNO₂ (424 mg, 6.15 mmol, 3.0 eq.) and PEG-400 (4.0 mL). The resulting mixture was stirred for 3 h at RT before addition ester 2

(600 mg, 2.05 mmol). After the reaction was completed, resulting mixture was added 40 mL of water and extracted with Et₂O (20 mL x 3). The combined organic layers were washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (10% EtOAc/hexane, R_f=0.33) to yield the *tert*-butyl 9-nitrononanoate **3** (234 mg, 44%). ¹H NMR (400 MHz, CDCl₃): δ 4.351 (2H, t, *J* = 7.2Hz), 2.18 (2H, t, *J* = 7.6), 1.99-1.94 (2H, m), 1.58-1.52(2H, m), 1.42 (9H, s), 1.37-1.29 (8H, m); ¹³C NMR (176 MHz, CDCl₃): δ 172.96, 79.72, 75.47, 35.28, 28.73, 28.66, 28.49, 27.90, 27.16, 25.96, 24.77; HRMS (ESI): calculated for C₁₃H₂₅NNaO₄ [M+Na⁺] 282.1676, found 282.1690.



To a solution of LAH (603 mg, 15.09 mmol) in THF (40 mL) was added dropwise undec-10ynoic acid (1338 mg, 7.95 mmol) in THF (10 mL) at 0 °C. After the reaction was completed, resulting mixture was added 10 mL of water at 0 °C and then adjusted to pH 3-5 using conc. HCl. The aqueous layer was extracted with Et₂O (100 mL x 3). The combined organic layers were washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo to give crude alcohol **4**. The crude alcohol **4** was used for next reaction without further purification. ¹H NMR (400 MHz, CDCl₃): δ 3.64 (t, J = 6.6 Hz, 2H), 3.49 (s, 1H), 2.18 (dt, J = 7.1, 2.6 Hz, 2H), 1.94 (t, J = 2.7 Hz, 1H), 1.63 – 1.47 (m, 4H), 1.46 – 1.21 (m, 10H); ¹³C NMR (100 MHz, CDCl₃): δ 84.92, 68.20, 63.20, 32.91, 29.57, 29.49, 29.16, 28.85, 28.60, 25.84, 18.53.

Alcohol 4 was dissolved in DCM (40 mL) followed by addition of PCC (2.23 g, 10.34 mmol) and celite (2.6 g) at 0 °C. After the reaction was completed, resulting mixture was filtered by celite and concentrated in vacuo. The residue was purified by flash chromatography (10%, EtOAc/hexane, R_f =0.53) to yield the aldehyde **5** (759 mg, 57% in two steps).[16] ¹H NMR (400 MHz, CDCl₃): δ 9.74 (1H, t, *J* = 1.6Hz), 2.40 (2H, td, *J* = 7.36, 1.84Hz), 2.16 (2H, td, *J* = 7.0, 2.64Hz), 1.92 (1H, t, *J* = 2.64Hz), 1.64-1.59 (3H, m), 1.53-1.46(2H, m), 1.40-1.35 (2H, m), 1.33-1.26(5H, m); ¹³C NMR (100 MHz, CDCl₃): δ 203.163, 84.901, 68.324, 44.092, 29.407, 29.285, 29.071, 28.842, 28.621, 22.247, 18.579 [16].



β-Hydroxynitro ester 6: To a solution of *tert*-butyl 9-nitrononanoate **3** (299 mg, 1.15 mmol) and aldehyde **5** (211 mg, 1.27 mmol, 1.1 eq.) in THF (6.0 mL) was added TMG (27 mg, 0.23 mmol, 0.2 eq.) dropwise at RT. After the reaction was completed, solvent was removed by reducing pressure and the residue was purified by flash chromatography (10% EtOAc/hexane, R_f =0.08) to yield the 45:55 mixture of diastereomers β-hydroxynitro ester **6** (332 mg, 68%). The mixture was used for next reaction without further purification.



((*E*)-9-nitroicos-9-en-19-ynoic acid 8: The β -hydroxynitro ester 6 (205 mg, 0.48 mmol) in round bottom flask was added acetic anhydride (3.0 mL) as solvent and a catalytic amount of *p*-toluenesulfonic acid (10 mg). The solution was stirred under N₂ at RT for overnight. After reaction was completed, the solvent was removed by azeotropic removal with toluene (3 × 20 mL) under reduced pressure. The residual was dissolved in toluene (3 mL) and addition of Na₂CO₃ (51 mg, 0.482 mmol, 1.0 eq.). The solution was heated to 90 °C under N₂ for overnight. After the reaction was completed, the solution is cooled to RT and diluted with 10 mL of NH₄Cl (sat.aq) and 10 mL Et₂O. After phase separation, the aqueous layer is extracted with Et₂O (10 mL x 3). The combined organic layers were washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo to afford nitroalkene products 7 and 8 as a mixture. The mixture was used for next reaction without further purification.

To the above mixture in DCM (3.0 mL) was added TFA (1.0 mL) at RT. After the reaction was completed, the solvent and excess TFA were removed by reducing pressure. The residual was purified by flash chromatography (20% EtOAc/hexane, R_f =0.42) to yield the (*E*)-9-nitroicos-9-en-19-ynoic acid **8** (69 mg, 41% in three steps). ¹H NMR (400 MHz, CDCl₃): δ 7.08 (1H, t, *J* = 7.6 Hz), 2.56 (2H, appear t), 2.35 (2H, t, J = 7.48), 2.24-2.16 (4H, m), 1.94 (1H, t, J = 2.64), 1.65-1.61 (3H, m), 1.54-1.44 (8H, m), 1.41-1.25(11H, m); ¹³C NMR (100 MHz, CDCl₃): δ 180.0, 151.7, 136.4, 84.6, 68.1, 33.9, 29.2, 29.1, 28.9, 28.84, 28.80, 28.6, 28.4, 28.3, 27.9, 27.8, 26.2, 24.5; HRMS (ESI): calculated for C₂₀H₃₂NO₄ [M–H⁺] 350.2337, found 350.2321.







mdd





S18

References

- [1] T. Cui, F.J. Schopfer, J. Zhang, K. Chen, T. Ichikawa, P.R.S. Baker, C. Batthyany, B.K. Chacko, X. Feng, R.P. Patel, A. Agarwal, B.A. Freeman, Y.E. Chen, Nitrated Fatty Acids: Endogenous Anti-inflammatory Signaling Mediators, J. Biol. Chem. 281 (2006) 35686–35698. https://doi.org/10.1074/jbc.M603357200.
- [2] E. Weerapana, C. Wang, G.M. Simon, F. Richter, S. Khare, M.B.D. Dillon, D.A. Bachovchin, K. Mowen, D. Baker, B.F. Cravatt, Quantitative reactivity profiling predicts functional cysteines in proteomes, Nature. 468 (2010) 790–795. https://doi.org/10.1038/nature09472.
- [3] M.M. Blewett, J. Xie, B.W. Zaro, K.M. Backus, A. Altman, J.R. Teijaro, B.F. Cravatt, Chemical proteomic map of dimethyl fumarate–sensitive cysteines in primary human T cells, Sci Signal. 9 (2016) rs10. https://doi.org/10.1126/scisignal.aaf7694.
- [4] J. Yang, K.A. Tallman, N.A. Porter, D.C. Liebler, Quantitative Chemoproteomics for Site-Specific Analysis of Protein Alkylation by 4-Hydroxy-2-Nonenal in Cells, Anal. Chem. 87 (2015) 2535–2541. https://doi.org/10.1021/ac504685y.
- [5] S.G. Codreanu, J.C. Ullery, J. Zhu, K.A. Tallman, W.N. Beavers, N.A. Porter, L.J. Marnett, B. Zhang, D.C. Liebler, Alkylation Damage by Lipid Electrophiles Targets Functional Protein Systems, Mol Cell Proteomics. 13 (2014) 849–859. https://doi.org/10.1074/mcp.M113.032953.
- [6] J.A. Clulow, E.M. Storck, T. Lanyon-Hogg, K.A. Kalesh, L.H. Jones, E.W. Tate, Competition-based, quantitative chemical proteomics in breast cancer cells identifies new target profiles for sulforaphane, Chem Commun (Camb). 53 (2017) 5182–5185. https://doi.org/10.1039/c6cc08797c.
- [7] M. Abo, E. Weerapana, A Caged Electrophilic Probe for Global Analysis of Cysteine Reactivity in Living Cells, J. Am. Chem. Soc. 137 (2015) 7087–7090. https://doi.org/10.1021/jacs.5b04350.
- [8] J. Wang, J. Zhang, C.-J. Zhang, Y.K. Wong, T.K. Lim, Z.-C. Hua, B. Liu, S.R. Tannenbaum, H.-M. Shen, Q. Lin, In situ Proteomic Profiling of Curcumin Targets in HCT116 Colon Cancer Cell Line, Sci Rep. 6 (2016) 22146. https://doi.org/10.1038/srep22146.
- [9] D. Abegg, R. Frei, L. Cerato, D. Prasad Hari, C. Wang, J. Waser, A. Adibekian, Proteome-Wide Profiling of Targets of Cysteine reactive Small Molecules by Using Ethynyl Benziodoxolone Reagents, Angewandte Chemie International Edition. 54 (2015) 10852–10857. https://doi.org/10.1002/anie.201505641.
- [10] G.K. Jarugumilli, J.-R. Choi, P. Chan, M. Yu, Y. Sun, B. Chen, J. Niu, M. DeRan, B. Zheng, R. Zoeller, C. Lin, X. Wu, Chemical Probe to Identify the Cellular Targets of the Reactive Lipid Metabolite 2-trans-Hexadecenal, ACS Chem. Biol. 13 (2018) 1130–1136. https://doi.org/10.1021/acschembio.7b01063.
- [11] M.M. Yore, A.N. Kettenbach, M.B. Sporn, S.A. Gerber, K.T. Liby, Proteomic Analysis Shows Synthetic Oleanane Triterpenoid Binds to mTOR, PLOS ONE. 6 (2011) e22862. https://doi.org/10.1371/journal.pone.0022862.
- [12] D. Davda, M.A. El Azzouny, C.T.M.B. Tom, J.L. Hernandez, J.D. Majmudar, R.T. Kennedy, B.R. Martin, Profiling Targets of the Irreversible Palmitoylation Inhibitor 2-Bromopalmitate, ACS Chem. Biol. 8 (2013) 1912–1917. https://doi.org/10.1021/cb400380s.
- [13] B. Zheng, M. DeRan, X. Li, X. Liao, M. Fukata, X. Wu, 2-Bromopalmitate Analogues as Activity-Based Probes To Explore Palmitoyl Acyltransferases, J. Am. Chem. Soc. 135 (2013) 7082–7085. https://doi.org/10.1021/ja311416v.

- [14] A. Kumari, S.P. Gholap, R.A. Fernandes, Tandem IBX-Promoted Primary Alcohol Oxidation/Opening of Intermediate β,γ-Diolcarbonate Aldehydes to (E)-γ-Hydroxy-α,βenals, Chemistry – An Asian Journal. 14 (2019) 2278–2290. https://doi.org/10.1002/asia.201900421.
- [15] M. Baalmann, L. Neises, S. Bitsch, H. Schneider, L. Deweid, P. Werther, N. Ilkenhans, M. Wolfring, M.J. Ziegler, J. Wilhelm, H. Kolmar, R. Wombacher, A Bioorthogonal Click Chemistry Toolbox for Targeted Synthesis of Branched and Well-Defined Protein–Protein Conjugates, Angewandte Chemie International Edition. 59 (2020) 12885–12893. https://doi.org/10.1002/anie.201915079.
- [16] X. Cheng, L. Li, M. Uttamchandani, S.Q. Yao, In Situ Proteome Profiling of C75, a Covalent Bioactive Compound with Potential Anticancer Activities, Org. Lett. 16 (2014) 1414–1417. https://doi.org/10.1021/ol500206w.